In a report published Friday, Jefferies analyst Brandon Couillard reiterated a Buy rating on EXACT Sciences Corporation EXAS, and raised the price target from $14.00 to $18.00.
In the report, Jefferies noted, “Our proprietary physician survey points to a strong launch for EXAS' novel colorectal cancer test (Cologuard) with significant interest amongst high-volume practitioners. We view the feedback as highly supportive of our intermediate-term volume assumptions that call for the test to penetrate 10% of its annual addressable market by 2016, and 20% by 2018. Our price target moves to $18 (from $14) on higher ASP and volume assumptions.”
EXACT Sciences Corporation closed on Thursday at $13.85.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in